[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567892":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":47,"collaborators":18,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":18,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":18,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":27,"whyStopped":18,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Zhejiang Cancer Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RLC-CRCHOP","EXPERIMENTAL","Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:\n\nrituximab 375mg\u002Fm2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.\n\nImmunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg\u002Fm2 d0, cyclophosphamide: 750mg\u002Fm2 d1, epirubicin: 75mg\u002F m2 d1 (or liposomal doxorubicin 35mg\u002Fm2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.\n\nmaintenance treatment period: chidamide d1,4,8,11",[13],"Drug: RLC-CRCHOP",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Chen Xi","CONTACT","+8617816890591","zjuchenxi@126.com",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Hangzhou","Zhejiang","310022","China","CN",{"type":34,"coordinates":35},"Point",[36,37],120.16142,30.29365,{"lat":37,"lon":36},[40,44,46],{"name":41,"role":22,"phone":42,"phoneExt":18,"email":43},"Haiyan Yang, PhD","0086-571-88122192","yanghy@zjcc.org.cn",{"name":45,"role":22,"phone":42,"phoneExt":18,"email":24},"Xi Chen, MD",{"name":45,"role":22,"phone":18,"phoneExt":18,"email":18},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Yang haiyan","Chief director of Lymphoma Department","100567892","phase-2-rlc-followed-by-cr-chop-in-elderly-patients-with-newly-diagnosed-del-100567892",false,"NCT06674096","RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL","Rituximab，Lenalidomide and Chidamide Followed by CR-CHOP in Elderly Patients with Newly-diagnosed Double-expressor Lymphoma","Inclusion Criteria:\n\n* 1\\. Untreated DLBCL patients confirmed by histopathology 2. Immunohistochemistry showed positive expression of MYC and BCL2 protein (double expressor lymphoma, MYC≥40%, BCL2≥50%) 3. age over 70 years old or age ≥65 years old and ECOG score ≥2 points, both male and female 4. Having at least one evaluable lesion, defined as having at least one lymphadenopathy with a maximum diameter \\> 1.5 cm, or at least one extranodal lesion with a maximum diameter \\> 1.0 cm, and at least two vertical diameters that can be accurately measured.\n\n  5\\. ECOG PS≤3 6. Expected survival time ≥3 months 7. voluntary participation in clinical research; Fully understand and understand the study and sign the informed consent; Willingness to follow and ability to complete all research steps.\n\nExclusion Criteria:\n\n* 1\\. The pathological subtypes were PCNSL, PMBCL, EBV-positive DLBCL and HGBL 2. Hemophagocytic syndrome accompanied the diagnosis 3. Central nervous system involvement is secondary to lymphoma 4. Are participating in other clinical studies, or the first study drug is administered less than 4 weeks after the end of treatment in the previous clinical study 5. HIV infection 6. Major surgery was performed within 28 days prior to study start 7. Any active infection that required systematic anti-infective therapy developed within 14 days prior to study initiation 8. The patients considered by the investigator to be unsuitable for participating in this study","ALL","65 Years",{"count":61,"type":62},44,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","This is a prospective, single-arm, multicenter clinical study to evaluate the efficacy and safety of chidamide, rituximab combined with lenalidomide sequential immunochemotherapy in the treatment of newly diagnosed elderly double-expressor diffuse large B-cell lymphoma.",[68],"Double-expressor Lymphoma",[70,71,72,73,74,75],"DLBCL","DEL","rituximab","lenalidomide","chidamide","chemo-free","2024-11-15",{"date":78,"type":79},"2024-11-18","ACTUAL",{"date":81,"type":62},"2024-11-06",{"date":83,"type":62},"2030-06-30",{"name":5,"class":6},1]